J&J launches biologic protein spray for sealing off bleeds during surgery

jnj
J&J’s work with the Barcelona-based Grifols includes the development of additional plasma-based devices for stopping surgical bleeds, as well as a deal to exclusively supply Ethicon with thrombin for a range of products over the next several years. (Wikimedia Commons)

Johnson & Johnson’s Ethicon unit has launched its blood-stopping protein spray, designed to quickly seal off and control excessive bleeding during open surgeries or minimally invasive procedures.

It’s the first product to graduate from the devicemaker’s collaboration with the plasma-focused Spanish multinational, Grifols. The Vistaseal biological sealant combines human fibrinogen and thrombin, two clotting agents found in the bloodstream.

According to Ethicon, it’s the first fibrin sealant designed to be used without a gas propellant. Delivered in a pre-filled syringe, the spray is designed to rapidly adhere and form a clot over the bleed, and has shown clinical success in high-risk patients—such as those with multiple factors including bleeding disorders, diabetes or organ failure, or patients taking blood thinners or antiplatelet therapies.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Across three randomized trials, Vistaseal demonstrated a lower overall hemostatic retreatment rate compared to standard treatments, the company said. Additionally, Ethicon estimates that between one- to two-thirds of open surgeries experience disruptive bleeding events.

"Vistaseal is the latest addition to our broad portfolio of primary and adjunctive hemostat solutions that address the growing and wide-ranging challenges surgeons face in managing bleeding," Ethicon’s global president of biosurgery, Oray Boston, said in a statement. According to Grifols, the device will be sold as Veraseal in markets outside the U.S.

RELATED: The top 10 medtech companies of 2024 | Johnson & Johnson

The Vistaseal system from Ethicon & Grifols (Ethicon)

The spray and applicator received a 510(k) clearance from the FDA in June to help control bleeding during procedures where standard surgery techniques—such as suturing, ligature or cauterization—are ineffective or impractical.

J&J’s collaboration with Grifols includes the development of additional plasma-based devices for stopping surgical bleeds, including a combination of Ethicon’s Surgiflo Hemostatic Matrix and Grifols’ freeze-dried thrombin protein. The absorbable Surgiflo porcine gelatin paste aims to provide a place for platelets to stick and form durable blood clots.

Ethicon previously tapped Grifols to exclusively supply the company with thrombin over a range of products across the next several years, including its Surgicel line of absorbable powder hemostats and its Evicel fibrin sealant for high-risk patients.

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.